Kite Pharma (Gilead Sciences)

Core Business

Kite Pharma, a wholly owned subsidiary of Gilead Sciences, is the world's leading CAR-T cell therapy company with approximately $1.8 billion in 2025 CGT product sales. Its flagship product Yescarta generated $1.5 billion in revenue, while Tecartus contributed $344 million. Kite operates four GMP-certified cell therapy manufacturing facilities across the US and Europe, achieving an industry-leading 14-day vein-to-vein turnaround time.

Global Presence

Headquartered in Santa Monica, California, Kite operates major manufacturing centers in El Segundo (CA), Frederick (MD), Oceanside (CA), and Amsterdam (Netherlands). Parent company Gilead Sciences operates in over 35 countries with 18,000+ employees. Kite's therapies are available across North America, Europe, and Asia-Pacific, treating thousands of patients annually. The company's dedicated cell therapy workforce exceeds 2,000 employees.

Key Strengths

Kite's primary competitive advantage lies in its proprietary internal manufacturing network — the largest and most efficient CAR-T production system globally. The company's 14-day average vein-to-vein time, combined with FDA REMS removal in early 2025, positions it for continued market leadership. Kite's deep hematology expertise, established payer coverage, and strategic partnership with Cytiva for the Sefia automated production platform create a formidable barrier to entry for competitors.

VerityRank Score

Kite Pharma (Gilead) achieves a VerityRank Score of 98/100, reflecting its dominant position in CAR-T commercialization, unparalleled internal manufacturing network, and global brand recognition in the CGT industry.